Efforts Continue to Expand Immunotherapy in CRC – OncLive
|
Efforts Continue to Expand Immunotherapy in CRC
OncLive However, the overwhelming majority of CRC patients are microsatellite-stable (MSS) and do not tend to respond well to single-agent immunotherapy, noted Johanna Bendell, MD. Researchers are are looking to improve immunotherapy options for these … |
